Real‐world efficacy of bictegravir/emtricitabine/tenofovir alafenamide regimen in patients infected with HIV‐1 sub‐subtype A6 harbouring the L74I mutation

Documenti analoghi

• Bictegravir/emtricitabine/tenofovir alafenamide in adults with HIV‐1 and end‐stage kidney disease on chronic haemodialysis
  di: Joseph J. Eron, et al.
  Pubblicazione: (2024)
• Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide in Black and Hispanic/Latine adults with HIV‐1 initiating first‐line therapy: 5‐year follow‐up from two phase III studies
  di: C. Martorell, et al.
  Pubblicazione: (2025)
• Rapid start with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as initial treatment in people with human immunodeficiency virus‐1 (HIV‐1): A systematic literature review of clinical and patient‐reported outcomes
  di: Jade Ghosn, et al.
  Pubblicazione: (2025)
• Effectiveness, safety, and patient‐reported outcomes of emtricitabine/tenofovir alafenamide‐based regimens for the treatment of HIV‐1 infection: Final 24‐month results from the prospective German TAFNES cohort study
  di: Christoph Stephan, et al.
  Pubblicazione: (2024)
• Authors' Reply to Letter to the Editor Regarding ‘Effectiveness, safety, and patient‐reported outcomes of emtricitabine/tenofovir alafenamide‐based regimens for the treatment of HIV‐1 infection: Final 24‐month results from the prospective German TAFNES cohort study’
  di: Christoph Stephan, et al.
  Pubblicazione: (2025)